A study to assess the effect of BMN 044 in subjects with Duchenne muscular dystrophy (Extension study)

• Register: EUCTR
• Last refreshed on: 8 August 2016
• Main ID: EUCTR2015-003681-87-BE
• Date of registration: 16/11/2015
• Prospective Registration: Yes
• Primary sponsor: BioMarin Pharmaceutical Inc.
• Public title: A study to assess the effect of BMN 044 in subjects with Duchenne muscular dystrophy (Extension study)
• Scientific title: A multi center, multi national, open label, extension study to evaluate the long-term efficacy and safety of BMN 044 (PRO044) in subjects with Duchenne muscular dystrophy
• Date of first enrolment: 12/01/2016
• Target sample size: 50
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003681-87
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no

Countries of recruitment

Belgium, Italy, Netherlands, Sweden, United States

Contacts

• Name: Clinical Trials Information
• Affiliation: BioMarin Pharmaceutical Inc.

• Name: Clinical Trials Information
• Affiliation: BioMarin Pharmaceutical Inc.

Key inclusion & exclusion criteria

Inclusion criteria:
1. Subjects previously treated with BMN 044 or a comparator treatment in a BMN 044 Sponsored Study or Investigator Initiated Trial and who are not eligible for another ongoing BMN 044 study. Subjects who withdrew from any previous BMN 044 study due to meeting laboratory safety stopping criteria may be eligible to enroll if the applicable laboratory parameter has resolved to be within normal limits or parent study baseline value, and benefit of further treatment with BMN 044 outweighs the risk to the individual subject, as agreed in consultation with the Medical Monitor.
2. Continued use of glucocorticosteroids for a minimum of 60 days prior to study entry with a reasonable expectation that the subject will remain on glucocorticosteroids for the duration of this study. Changes to or cessation of glucocorticosteroids will be at the discretion of the Investigator conducting this study in consultation with the subject/parent and Medical Monitor. Subjects who have discontinued glucocorticosteroids in their previous BMN 044 study, following consultation with the Medical Monitor may be enrolled.
3. Willing and able to comply with all study requirements and procedures.
4. Willing and able to provide written, signed informed consent, or in the case of subjects under the age of 18 years(or 16 years, depending on the region), provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to the conduct of any research-related procedures.

Are the trial subjects under 18? yes
Number of subjects for this age range: 50
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 2
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Subjects who have previously been treated with BMN 044 who had a serious adverse experience or met safety stopping criteria that remains unresolved, which in the opinion of the Investigator could have been attributable to BMN 044. Once resolved, subject may be eligible to enter the study following Investigator consultation with the Medical Monitor.
2. History of significant medical disorder which may confound the interpretation of safety data (e.g. current or history of renal or liver disease/impairment, history of inflammatory illness, bleeding complications, mental retardation and/or behavioral problems).
3. Acute illness within 4 weeks prior to the first dose of BMN 044 (Week 1) which may interfere with the measurements.
4. Symptomatic cardiomyopathy. If subject has a left ventricular ejection fraction <45% at start of this study, the Investigator should discuss inclusion of subject in this study with the Medical Monitor.
5. Baseline aPTT above the upper limit of normal (ULN). A re test is possible at a later stage, and if within normal range, the subject may enter the study.
6. Baseline platelet count below the lower limit of normal (LLN). A re test is possible at a later stage, and if within normal range, the subject may enter the study.
7. Use of anti coagulants, anti thrombotics or anti platelet agents within 28 days of the baseline visit. Chronic use of anti coagulants, anti thrombotics or anti platelet agents is prohibited during the study. As needed dosing (pro re nata – PRN) may be acceptable (except for aspirin) following discussion with the Medical Monitor.
8. Prior use of any investigational product (other than BMN 044) or investigational medical device must be discussed with the Medical Monitor prior to screening.
9. Current or history of drug and/or alcohol abuse.



Age minimum:
Age maximum:
Gender:
Female: no
Male: yes

Health Condition(s) or Problem(s) studied

Duchenne muscular dystrophy
MedDRA version: 18.1 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disorders

Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

Intervention(s)

Product Name: BMN 044
Product Code: BMN 044
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: PS188 (company code)
CAS Number: 1802402-63-6
Current Sponsor code: PS188
Other descriptive name: PS188
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 200-

Product Name: BMN 044
Product Code: BMN 044
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: PS188 (company code)
CAS Number: 1802402-63-6
Current Sponsor code: PS188
Other descriptive name: PS188
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 100-

Primary Outcome(s)

Main Objective: • To evaluate the long-term safety of BMN 044 in subjects with DMD correctable by BMN 044 induced DMD exon 44 skipping who have previously participated in an eligible study

Timepoint(s) of evaluation of this end point: Please refer to Section 12.3.2 Study period procedures and assessments in the Protocol

Secondary Objective: Treatment Period 1:
• To evaluate the long-term efficacy of the dosing regimens used in prior BMN 044 studies.
• To evaluate the long-term safety and tolerability of the dosing regimens used in prior BMN 044 studies.

Treatment Period 2:
• To evaluate the long-term efficacy of a selected dosing regimen(s) for BMN 044.
• To evaluate the long-term safety and tolerability of a selected dosing regimen(s) for BMN 044.
• To evaluate the long-term impact on patient reported outcomes of continued treatment with BMN 044.

Primary end point(s): Efficacy:
Ambulant subjects:
• Muscle function using:
- 6 minute walking distance (6MWD) test
- Timed function tests (4 stair climb, Rise from floor, 10 meter walk/run)
• North Star Ambulatory Assessment
• Patient Reported Outcomes Measure (PROM), Patient Outcomes Data Collection Instrument (PODCI), EQ 5D 5L
• Pulmonary function (forced expiratory volume in the 1st second of exhalation [FEV1], forced vital capacity [FVC], Maximum Inspiratory Pressure [MIP], Maximum Expiratory Pressure [MEP], Peak Cough Flow [PCF], and Peak Flow [PF])
• Time to major disease milestones (e.g. loss of ambulation, night time ventilation)
• Performance Upper Limb (PUL)
Non-ambulant subjects:
• Pulmonary function (FEV1, FVC, MIP, MEP, PCF, and PF)
• Time to major disease milestones (e.g. night time ventilation)
• PUL
• Egen Klassification
• PROM, PODCI, EQ 5D 5L
Safety:
• Incidence and severity of adverse events
• Vital signs
• ECG parameters
• Injection Site Reactions
• Safety hematology and biochemistry parameters including non-standard parameters such as coagulation parameters (in particular aPTT), serum cystatin C, Complement Factor C3/C4/H, haptoglobin, fibrinogen, high sensitivity C-reactive protein (hsCRP)
• Urinalysis (including quantitative protein and creatinine and their ratio)
• Anti-dystrophin antibodies and anti-BMN 044 antibodies
Pharmacodynamic:
• Serum Creatine Kinase (CK), lactate dehydrogenase (LDH) and other biomarkers to be defined
Pharmacokinetic:
• Plasma PK pre-dose every 24 weeks

Secondary Outcome(s)

Secondary end point(s): n/a

Timepoint(s) of evaluation of this end point: n/a

Secondary ID(s)

BMN-044-201

Source(s) of Monetary Support

BioMarin Pharmaceutical Inc.